Can Aliskiren be Considered as a New Novel Drug for Hypertension?

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Hypertension is a leading global cause of mortality.
• Numerous therapeutic strategies exist for hypertension management.
• Direct renin inhibitors (DRIs) represent a new drug class targeting the renin-angiotensin system (RAS).

Purpose of the Study:

• To evaluate the clinical utility of direct renin inhibitors (DRIs) in hypertension management.
• To review existing trial data on monotherapy and combination therapy with DRIs.
• To assess factors such as compliance, adverse effects, and cost associated with DRIs.

Main Methods:

• Review of multiple clinical trials investigating direct renin inhibitors (DRIs).
• Analysis of data concerning monotherapy versus combination therapy outcomes.
• Examination of patient compliance, adverse events, and economic factors.

Main Results:

• Direct renin inhibitors (DRIs) block the initial step of the renin-angiotensin system (RAS).
• Clinical trial outcomes for DRI monotherapy and combination therapy are under debate.
• Compliance, adverse effects, and cost are significant considerations for DRIs.

Conclusions:

• Direct renin inhibitors (DRIs) offer a targeted approach to blocking the renin-angiotensin system (RAS).
• Further extensive studies are required to establish the definitive clinical role of DRIs in hypertension treatment.
• The long-term benefits, safety profile, and cost-effectiveness of DRIs warrant continued investigation.